VANCOUVER, Jan. 22 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced that the underwriters of its cross-border public
offering of 8,000,000 common shares that was priced on January 18, 2007,
exercised the over-allotment option in full to purchase an additional
1,200,000 common shares at a price of US$10.50 per share. Net proceeds from
the offering (including the common shares to be issued pursuant to the
exercise of the over-allotment option) are expected to be approximately
US$90 million.
